Lonza buys Micro-Macinazione to bolster micronization biz

By Gareth Macdonald contact

- Last updated on GMT

iStock/herraez
iStock/herraez
Lonza Group AG has acquired API processing firm Micro-Macinazione SA from private equity investor Cross Equity SA.  

The takeover – which was completed on July 26 – includes Micro-Macinazione’s active pharmaceutical ingredient (API) processing site and recently expanded​ warehouse in Monteggio, Switzerland.

A Lonza spokesman told us: “Micro-Macinazione has 120 employees and is based in Monteggio, Switzerland. We will take over the entire site.

He added that: “Micro-Macinazione provides micronization technology and expertise that complements our existing US capabilities and provides significant additional capacity to support our growth​.”

Lonza said demand for micronization and sub-micronization is increasing as customers seek to improve the bioavailability and efficacy of their products.

The Swiss life science supplier’s main drug ingredient micronization capabilities are located at a facility in Quakertown, Pennsylvania that is owned by recent acquisition Capsugel​.

News of the acquisition comes a little over a year​ after Capsugel said it planned to increase micronization capacity at the Quakertown site.

Small molecules, major driver

In July Lonza predicted it will generate annual revenue of CHF7.5bn ($7.9bn) by 2022 citing the expansion of its offering provided by Capsugel as an important driver.

The firm reported that its harma&biotech segment generated revenue of CHF1.06bn in the first half of 2017, up 27% on the equivalent period last year.

It cited “positive performance within chemical manufacturing” adding that “Small molecules made a significant improvement compared to the prior year due to better commercial offerings to existing and new customers.”

Related news

Show more

Related products

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers